Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis
Rev. panam. salud p£blica
; 24(5): 304-313, Nov. 2008. tab, ilus, graf
Artigo
em Inglês
| MedCarib
| ID: med-17457
Biblioteca responsável:
TT5
Localização: TT5; W1, RE712AW
ABSTRACT
OBJECTIVE:
In Latin America and the Caribbean, routine vaccination of infants against Streptococcus pneumoniae would need substantial investment by governments and donor organizations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate vaccine, demographic, epidemiologic, and cost data into an economic analysis of pneumococcal vaccination of infants in Latin America and the Caribbean.METHODS:
We previously used a structured literature review to develop regional estimates of the incidence of disease. Cost data were collected from physician interviews and public fee schedules. We then constructed a decision analytic model to compare pneumococcal conjugate vaccination of infants with no vaccination across this region, examining only vaccine's direct effects on children.RESULTS:
Pneumococcal vaccination at the rate of diphtheria-tetanus-pertussis vaccine coverage was projected to prevent 9500 deaths per year in children aged 0 to 5 years in the region, or approximately one life saved per 1 100 infants vaccinated. These saved lives as well as averted cases of deafness, motor deficit, and seizure result in 321000 disability-adjusted life years (DALYs) being averted annually. At vaccine prices between US$5 and US$53 per dose, the cost per DALY averted from a societal perspective would range from US$154 to US$5252.CONCLUSION:
Pneumococcal conjugate vaccine was highly cost-effective up to $40 per dose. Introduction of pneumococcal vaccine in the Latin American and Caribbean region is projected to reduce childhood mortality and to be highly cost-effective across a range of possible costs.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
/
Doenças Negligenciadas
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
/
ODS3 - Meta 3.2 Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
Problema de saúde:
Objetivo 4: Financiamento para a saúde
/
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
Meta 3.2: Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
/
Doenças Negligenciadas
/
Zoonoses
/
Meningite
/
Pneumonía
/
Sepse
/
Outras Doenças Respiratórias
/
Infecções
Base de dados:
MedCarib
Assunto principal:
Streptococcus pneumoniae
/
Árvores de Decisões
/
Custos e Análise de Custo
/
Vacinas Pneumocócicas
Tipo de estudo:
Avaliação econômica em saúde
/
Estudo prognóstico
/
Pesquisa qualitativa
Aspecto:
Preferência do paciente
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. panam. salud p£blica
Ano de publicação:
2008
Tipo de documento:
Artigo
Instituição/País de afiliação:
Departamento de Salud P£blica y Epidemiolog¡a/Chile
/
Direcci¢n General de Epidemiolog¡a/Republica Dominicana
/
Facultad de Medicina/Colombia
/
Independent consultant/United States of America
/
Respiratory Diseases Branch/United States of America
/
Sabin Vaccine Institute/United States of America
/
Universidad CES/Colombia
/
University of Medicine and Dentistry of New Jersey/United States of America